Causes and consequences of discontinuation of GLP1RAs or tirzepatide.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing literature without systematic search or meta-analytic methodology
PubMed 42168641 · doi:10.1038/s41574-026-01258-5
What was done
This narrative review synthesized literature examining the drivers and cardiometabolic consequences of discontinuing glucagon-like peptide 1 (GLP1) receptor agonists and tirzepatide among individuals treated for type 2 diabetes mellitus and/or overweight or obesity.
What was found
No quantitative statistics or effect estimates were reported in the abstract. Suboptimal real-world persistence was noted within the first year of therapy, driven by gastrointestinal side effects, insufficient efficacy, financial costs, and fear of rare adverse effects. Discontinuation is associated with weight regain, deterioration in cardiometabolic risk profiles, and weight and HbA1c fluctuations from treatment cycling. The abstract notes that few data exist on hard clinical cardiovascular outcomes after discontinuation.
Why it matters
Because the clinical benefits of incretin-based therapies diminish upon cessation, high real-world discontinuation rates and subsequent risk factor rebound represent a major challenge for long-term cardiorenal disease prevention.
Limits
This is a narrative review rather than a systematic review or meta-analysis. The abstract provides no sample sizes, numerical effect sizes, or counts of analyzed studies, and explicitly notes a lack of hard outcome data following discontinuation.
Cited by
- supports Approximately 60% of people who initiate GLP-1 agonist therapy discontinue the medication within one to two years.